Avendus Capital Pvt.Ltd.
IPOs where Avendus Capital Pvt.Ltd. acted as a book-running lead manager, with each issue’s size and listing outcome.
Track record on ipostation
ipostation's database lists Avendus Capital Pvt.Ltd. as a book-running lead manager on 5 IPOs: all of them mainboard issues. Bidding dates recorded here run from Aug 2026 to Oct 2026. Of these, 3 have listed and 2 are between scheduling and listing. It shared every one of these mandates with at least one other lead manager.
Issue size is recorded for all 5 IPOs. They range from ₹475.48 Cr (Sahajanand Medical Technologies) to ₹22,562.71 Cr (NSE), with a median of ₹2,480 Cr. The 3 listed issues with a recorded size total ₹26,799.71 Cr; sizes for issues that have not listed are the amounts stated in their offer documents.
A listing-day change is recorded for 3 listed issues: 2 above and 1 below the issue price. The median change was +0.8%, from -1.0% (Symbiotec Pharmalab) to +4.4% (LEAP India). These are past listing outcomes and say nothing about how a future issue will list.
Final overall subscription is recorded for all 3 issues whose bidding has closed. The median was 8.82x, ranging from 5.71x (NSE) to 75.08x (Symbiotec Pharmalab).
Currently between scheduling and listing: Sahajanand Medical Technologies and Zetwerk.
Avendus Capital Pvt.Ltd. has worked alongside 21 other lead managers on these issues. The 5 most frequent, by number of shared issues:
- JM Financial Ltd. — 4 shared issues
- HSBC Securities & Capital Markets (India) Pvt.Ltd. — 3 shared issues
- Motilal Oswal Investment Advisors Ltd. — 3 shared issues
- IIFL Capital Services Ltd. — 2 shared issues
- Kotak Mahindra Capital Co.Ltd. — 2 shared issues
IPOs with Avendus Capital Pvt.Ltd. as lead manager
| IPO | Board | Status | Open date | Issue size | Price | Subscription | Listing gain |
|---|---|---|---|---|---|---|---|
| Sahajanand Medical Technologies | Mainboard | Open | 15 Oct 2026 | ₹475.48 Cr | ₹344 | — | — |
| Zetwerk | Mainboard | Open | 15 Oct 2026 | ₹5,012.33 Cr | ₹151 | — | — |
| NSE | Mainboard | Listed | 17 Sept 2026 | ₹22,562.71 Cr | ₹1,785 | 5.71x | +0.8% |
| Symbiotec Pharmalab | Mainboard | Listed | 24 Aug 2026 | ₹1,757 Cr | ₹988 | 75.08x | -1.0% |
| LEAP India | Mainboard | Listed | 7 Aug 2026 | ₹2,480 Cr | ₹159 | 8.82x | +4.4% |
Subscription is the final overall figure once bidding has closed; listing gain is the listing-day change against the issue price. “—” means not available.
What a book-running lead manager does
Under Regulation 23 of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, an issuer must appoint one or more SEBI-registered merchant bankers, at least one of whom is a lead manager to the issue. When more than one merchant banker manages an issue, each one’s responsibilities for disclosures, allotment, refunds and underwriting are fixed in advance and set out in the draft offer document and the offer document.